Universitaetsklinikum Heidelberg AöR — Sponsor Intelligence | 37 EU Trials

Filter these 37 trials by condition, phase, country and more.

Open in Search →

37 Registered trials

20 Recruiting

13 Completed trials

8 Countries active

76 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase I (Other)

Phase III: 9 Phase II/III: 1 Phase II: 12 Phase I/II: 5 Phase IV: 4 Phase I: 1 Phase I (Other): 4 Other: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

13 of 13 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Idiopathic inflammatory myopathy 2 Systemic lupus erythematosus 2 Psoriatic arthropathy 1 Arteriosclerosis coronary artery 1 Colorectal cancer metastatic 1 Colitis ulcerative 1 Chronic kidney disease 1 Hypoplastic left heart syndrome 1 Rheumatoid arthritis 1 Axial spondyloarthritis 1 Glioblastoma 1

Top IMPs

BORTEZOMIB 3 ISATUXIMAB 3 LENALIDOMIDE 3 GUSELKUMAB 2 IXEKIZUMAB 2 UPADACITINIB 2 ABATACEPT 1 ANAKINRA 1 APREMILAST 1 ASCORBIC ACID 1 ATEZOLIZUMAB 1 AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+ 1

All trials — page 2

37 total

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retrovir… Recruiting

2024-516832-82-00 Phase I/II 1 country T LYMPHOCYTES TRANSDUCED WITH A RV-SFG.CD19.CD28.4-1BBZETA RETROVIRAL VECTOR
Inhibition of JAK enzymes in early stage joint inflammation Ended

2024-514026-23-00 Phase II 1 country
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA … Ended

2024-516590-75-00 Phase II 1 country ATEZOLIZUMAB; CARBOPLATIN; PACLITAXEL ALBUMIN-BOUND
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Phase III 1 country BORTEZOMIB; ISATUXIMAB; LENALIDOMIDE
Assessment of the exposure-dependent perpetrator characteristics of metamizole on metabolic pathways and the pharmacokinetics of imatinib in… Ended

2024-513463-96-01 Phase I (Other) 1 country
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col… Ended

2023-509771-17-00 Phase II/III 1 country
Rapid pain control in Ixekizumab targeted axial spondyloarthritis Ended

2023-508976-12-00 Phase IV 1 country IXEKIZUMAB
Finerenone and renal oxidative stress Ended

2023-508266-15-00 Phase III 1 country ASCORBIC ACID; FINERENONE; IOHEXOL
Assessment of the influence of the gut microbiome on tacrolimus pharmacokinetics in healthy volunteers Ended

2023-504405-37-00 Phase I (Other) 1 country
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOr… Ended

2024-514225-30-00 Phase I 1 country
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Phase III 2 countries BORTEZOMIB; ISATUXIMAB; LENALIDOMIDE
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing Ended

2024-512669-15-00 Phase IV 1 country UPADACITINIB
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary… Ended

2024-517065-16-00 Phase II 1 country

Showing 25–37 of 37 trials

← All sponsors A–Z